Projects: Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Size: px
Start display at page:

Download "Projects: Neoplasms benign, malignant and unspecified (incl cysts and polyps)"

Transcription

1 Erstellung einer Stellungnahme für den G-BA zur Nutzenbewertung eines VEGF-Rezeptor Hemmers Other Preparation of a response document for the G-BA benefit assessment Erstellung eines Dossiers für eine Nutzenbewertung gemäß Paragraph 35a SGB V für einen VEGF-Rezeptor Hemmer Other Preparation of a value dossier according to para 35a SGB V A pharmacodynamic equivalence study on intramuscular versus subcutaneous application of an LH-RH analogon in patients with advanced prostate cancer A pharmacodynamic equivalence study on intramuscular versus subcutaneous application of an LH-RH analogon in patients with advanced prostate cancer Ethics commitee procedure and authorities Sample size: 100 Page 1 of 7

2 Überprüfung einer statistischen Auswertung auf Plausibilität und Richtigkeit durch einen Statistiker Other Sample size: 600 Publikationsservice für Anwendungsbeobachtung Prostatakarzinom Other Publication A pharmacodynamic equivalence study on intramuscular versus subcutaneous application of an LH-RH analogon in patients with advanced prostate cancer Review of documents Ethics commitee procedure and authorities Reimbursement according to ICH Topic E 3 Sample size: 100 Phase III Study of a multi-targeted receptor tyrosine kinase inhibitor in Subjects with Advanced Renal Cell Cancer prior to Radical Kidney Surgery, study protocol Review of documents Ethics commitee procedure and authorities I Page 2 of 7

3 A multicenter, randomized, double-blind, phase 3 study in patients with advanced/metastatic non-small cell lung cancer I Sample size: 90 A phase II open-label, multi-centre, randomised, prospective, parallel-group study comparing two cytostatic drugs as second line treatment in patients with relapsed extensive disease small cell lung cancer Sample size: 225 Anwendungsbeobachtung mit einem Hormon bei Patienten mit Prostata-Karzinom Non-interventional study Recruitment of sites Notification to authorities Reimbursement Statistical report Sample size: 500 Page 3 of 7

4 A randomized, double-blind, placebo-controlled trial of the prevention and treatment of chemotherapy-induced peripheral neuropathy symptoms with a new substance in subjects with advanced colorectal cancer Pharmacovigilance I Sample size: 10 Telefoninterviews mit Prüfzentren zur Einholung von Feasibility-Checks für eine Studie bei Mamma-Karzinom Other Telephone interviews within the scope of feasibility checks Zytostatikum in der second-line Therapie bei Patienten mit kleinzelligem Bronchialkarzinom Additional statistical analysis Sample size: 170 A trial of a monoclonal anti-idiotype antibody in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer according to ICH Topic E 3 Phase: I/II Sample size: 36 Diagnostik des Prostatakarzinoms bei Patienten mit benigner Prostatahyperplasie - offene, prospektive Phase-IV-Studie Conception of study design Statistical planning Phase: IV Sample size: 132 Page 4 of 7

5 A randomised, single-centre, double-blind, placebo-controlled, parallel-group pilot study evaluating the efficacy of a natural ointment in breast cancer patients with secondary lymphoedema Statistical planning I Sample size: 30 Anwendungsbeobachtung zur additiven Therapie mit einem Phytopharmakon bei Patientinnen mit Mamma-Karzinom und adjuvanter Chemotherapie Non-interventional study Reimbursement Sample size: 271 Phase I trial of a monoclonal anti-idiotype antibody in patients with epithelial ovarian, fallopian tube, or peritoneal cancer according to ICH Topic E 3 Phase: I Sample size: 42 Page 5 of 7

6 Anti-idiotype vaccine for patients with advanced ovarian carcinomas with an murine monoclonal anti-idiotype antibody - Determination of immunological therapy effect Statistical report Phase: Ib/II Sample size: 119 Anwendungsbeobachtung mit einem pflanzlichen Arzneimittel in der Nachsorgebehandlung von Patienten mit malignen Tumoren Non-interventional study Sample size: 906 Zytostatikum in der second-line Therapie bei Patienten mit kleinzelligem Bronchialkarzinom Sample size: 170 Page 6 of 7

7 Klinische Studie mit einem pflanzlichen Arzneimittel in der Nachsorgebehandlung von Patienten mit malignen Tumoren Phase: IV Sample size: 200 Page 7 of 7

Ramucirumab (colorectal cancer)

Ramucirumab (colorectal cancer) IQWiG Reports Commission No. A16-50 Ramucirumab (colorectal cancer) Addendum to Commission A16-10 1 Addendum Commission:A16-50 Version: 1.0 Status: 27 July 2016 1 Translation of addendum A16-10 Ramucirumab

More information

European Medicines Agency decision

European Medicines Agency decision EMA/738884/2013 European Medicines Agency decision P/0004/2014 of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bevacizumab (Avastin), (EMEA-000056-PIP01-07-M02)

More information

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles 2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla

More information

Perfomance in Delivering (Commercial Trials)

Perfomance in Delivering (Commercial Trials) Perfomance in Delivering (Commercial Trials) REC Ref IRAS ID Name of Trial Target Of? Minimum Of Maximum Of Target Date To Recruit? Total Date Of to recruit target number Recruited At of patients The Target

More information

Nivolumab Addendum to Commission A

Nivolumab Addendum to Commission A IQWiG Reports Commission No. A15-58 Nivolumab Addendum to Commission A15-32 1 Addendum Commission:A15-58 Version: 1.0 Status: 13 January 2016 1 Translation of addendum A15-58 Nivolumab Addendum zum Auftrag

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1113-6 Program Prior Authorization/Notification Medication Votrient TM (pazopanib) P&T Approval Date 1/12/2010, 9/2010, 12/2010,

More information

Mepolizumab (asthma)

Mepolizumab (asthma) IQWiG Reports Commission No. A16-33 Mepolizumab (asthma) Addendum to Commission A16-03 1 Addendum Commission:A16-33 Version: 1.0 Status: 29 June 2016 1 Translation of addendum A16-33 Mepolizumab (Asthma)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/738885/2013 European Medicines Agency decision P/0005/2014 of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bevacizumab (Avastin), (EMEA-000056-PIP03-10-M02)

More information

The OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools

The OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and

More information

Empagliflozin (type 2 diabetes mellitus)

Empagliflozin (type 2 diabetes mellitus) IQWiG Reports Commission o. A16-46 Empagliflozin (type 2 diabetes mellitus) Addendum to Commission A16-12 1 Addendum Commission:A16-46 Version: 1.0 Status: 29 July 2016 1 Translation of addendum A16-46

More information

Trial record 1 of 1 for:

Trial record 1 of 1 for: Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,

More information

Open Trials as of end of March 2016

Open Trials as of end of March 2016 EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG

More information

Summary of Strategic Competitive Analysis and Publication Planning

Summary of Strategic Competitive Analysis and Publication Planning Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing

More information

NCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17

NCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17 OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay

More information

Empagliflozin/metformin

Empagliflozin/metformin IQWiG Reports Commission No. A16-13 Empagliflozin/metformin Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Empagliflozin/Metformin

More information

For personal use only

For personal use only ASX/Media Release (Code: PRR) 14 September 2011 CVac TM Phase III CANVAS Ovarian Cancer Clinical Update Highlights Upcoming CVac Phase III trial to be named CANVAS CANcer VAccine Study Successful progress

More information

Medication Prior Authorization Form

Medication Prior Authorization Form Policy Number: 1047 Eligard (leuprolide acetate) 7.5mg Eligard (leuprolide acetate) 22.5mg Eligard (leuprolide acetate) 30mg Eligard (leuprolide acetate)45mg Firmagon (degarelix) Lupaneta Pack (leuprolide

More information

Avastin (bevacizumab)

Avastin (bevacizumab) Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin

More information

Operative Urology PDF OPERATIVE UROLOGY. PDF File: Operative Urology 1

Operative Urology PDF OPERATIVE UROLOGY. PDF File: Operative Urology 1 OPERATIVE UROLOGY PDF File: Operative Urology 1 RELATED BOOK : Benigne Prostatahyperplasie urology guide com Die benigne Prostatahyperplasie (BPH) bezeichnet eine gutartige Vergr erung der Prostata. In

More information

Media Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011

Media Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011 Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived

More information

3 Summary of clinical applications and limitations of measurements

3 Summary of clinical applications and limitations of measurements CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin-16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant

More information

CARBOplatin (AUC4-6) Monotherapy-21 days

CARBOplatin (AUC4-6) Monotherapy-21 days INDICATIONS FOR USE: CARBOplatin (AUC4-6) Monotherapy-21 days INDICATION ICD10 Regimen Code First line adjuvant therapy of ovarian carcinoma of epithelial origin C56 00261a primary peritoneal carcinoma

More information

NCCP Chemotherapy Protocol. Carboplatin Monotherapy-21 days

NCCP Chemotherapy Protocol. Carboplatin Monotherapy-21 days Carboplatin Monotherapy-21 INDICATIONS FOR USE: INDICATION ICD10 Protocol Code First line adjuvant therapy of ovarian carcinoma of epithelial origin primary peritoneal carcinoma fallopian tube cancer C56

More information

Performance in delivering Clinical Research at PHT Q3 14/15 study met the 70 day target study within 70 day target study not met 70 day target

Performance in delivering Clinical Research at PHT Q3 14/15 study met the 70 day target study within 70 day target study not met 70 day target Performance in delivering Clinical Research at PHT Q3 14/15 study met the 70 day target study within 70 day target study not met 70 day target Research Ethics Committee 14/ES/0004 ALA-BCC-CT008 - A randomized,

More information

Sofosbuvir/velpatasvir (chronic hepatitis C)

Sofosbuvir/velpatasvir (chronic hepatitis C) IQWiG Reports Commission No. A16-73 Sofosbuvir/velpatasvir (chronic hepatitis C) Addendum to Commission A16-48 1 Addendum Commission:A16-73 Version: 1.0 Status: 8 December 2016 1 Translation of addendum

More information

TRUST Trial on Radical Upfront Surgical Therapy

TRUST Trial on Radical Upfront Surgical Therapy AGO OP.7 / TRUST TRUST Trial on Radical Upfront Surgical Therapy A close international cooperation ENGOT ov33 Ongoing Trials status update AGO-OVAR OP.7 / TRUST ENGOT-ov33 Trial setting: Sponsor: Pt with

More information

Draft Agreed by Biosimilar Working Party (BMWP) October Adoption by CHMP for release for consultation 17 November 2011

Draft Agreed by Biosimilar Working Party (BMWP) October Adoption by CHMP for release for consultation 17 November 2011 1 2 3 17 November 2011 EMA/CHMP/BMWP/671292/2010 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on non-clinical and clinical development of similar biological medicinal products

More information

Putting NICE guidance into practice

Putting NICE guidance into practice Putting NICE guidance into practice Resource impact report: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after

More information

Linagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1

Linagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1 IQWiG Reports Commission No. A12-11 Linagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment ( Linagliptin

More information

by HepaWash BREAKTHROUGH IN MULTI ORGAN SUPPORT! One single device for liver, lung and kidney support ADVOS ADVanced Organ Support

by HepaWash BREAKTHROUGH IN MULTI ORGAN SUPPORT! One single device for liver, lung and kidney support ADVOS ADVanced Organ Support ADVOS by HepaWash BREAKTHROUGH IN MULTI ORGAN SUPPORT! One single device for liver, lung and kidney support ADVOS ADVanced Organ Support ADVOS: First treatment worldwide for individualized multi organ

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 REMOVAB 10 microgram concentrate for infusion solution Carton containing 1 pre-filled syringe (CIP:

More information

Votrient. Votrient (pazopanib) Description

Votrient. Votrient (pazopanib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.83 Subject: Votrient Page: 1 of 6 Last Review Date: December 2, 2016 Votrient Description Votrient

More information

Votrient. Votrient (pazopanib) Description

Votrient. Votrient (pazopanib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.83 Subject: Votrient Page: 1 of 6 Last Review Date: June 22, 2018 Votrient Description Votrient (pazopanib)

More information

Bernstr. 13, 3550 Langnau, Switzerland, *Dept of Mathematical Statistics, University of Berne, 3012 Berne, Switzerland. Correspondence to HUA.

Bernstr. 13, 3550 Langnau, Switzerland, *Dept of Mathematical Statistics, University of Berne, 3012 Berne, Switzerland. Correspondence to HUA. Medical Hypotheses (1998) 51, 315-320 Harcourt Brace & Co. Ltd 1998 Febrile history infectious of cancer childhood diseases in the patients and matched controls H. U. ALBONICO, H. U. BRAKER*, J. HUSLER*

More information

Improving outcomes as rapidly as possible for patients. Multi-arm, multi stage platform, umbrella and basket protocols

Improving outcomes as rapidly as possible for patients. Multi-arm, multi stage platform, umbrella and basket protocols Improving outcomes as rapidly as possible for patients Multi-arm, multi stage platform, umbrella and basket protocols Mahesh Parmar MRC Clinical Trials Unit at UCL Institute of Clinical Trials and Methdology

More information

Kombination von Checkpointinhibitoren beim malignen Melanom

Kombination von Checkpointinhibitoren beim malignen Melanom Kombination von Checkpointinhibitoren beim malignen Melanom Dirk Jäger Medizinische Onkologie Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg Ipilimumab beim metastasierten Melanom

More information

Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union

Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans Presented by: Richard Veselý An agency of the European Union Adalimumab - Crohn s disease Indication: Treatment of severe,

More information

Kann die konfokale Mikroskopie Nachresektionen ersparen?

Kann die konfokale Mikroskopie Nachresektionen ersparen? Kann die konfokale Mikroskopie Nachresektionen ersparen? Ist der Pathologe ersetzbar?, B. Papassotiropoulos, Z. Varga, L. Moskovszky, M. Nap, U. Gueth, A. Baege, E. Amann, F. Chiesa, C. Tausch In der Diagnostik

More information

Osimertinib (lung cancer)

Osimertinib (lung cancer) IQWiG Reports Commission No. A16-14 Osimertinib (lung cancer) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Osimertinib

More information

Impact of zoledronic acid on control of metastatic spinal cord compression

Impact of zoledronic acid on control of metastatic spinal cord compression Strahlenther Onkol 2012 188:910 916 DOI 10.1007/s00066-012-0158-4 Received: 16 May 2012 Accepted: 30 May 2012 Published online: 18. August 2012 Springer-Verlag 2012 D. Rades 1 S.G. Hakim 2 A. Bajrovic

More information

NCCP Chemotherapy Regimen. Bevacizumab 15mg/kg Therapy 21 days

NCCP Chemotherapy Regimen. Bevacizumab 15mg/kg Therapy 21 days Bevacizumab 15mg/kg Therapy 21 days INDICATIONS FOR USE: INDICATION ICD10 Regimen Code In combination with carboplatin and paclitaxel is indicated for the frontline 00215a treatment of adult patients with

More information

Eribulin (liposarcoma)

Eribulin (liposarcoma) IQWiG Reports Commission No. A16-65 Eribulin (liposarcoma) Addendum to Commission A16-31 1 Addendum Commission:A16-65 Version: 1.0 Status: 10 November 2016 1 Translation of addendum A16-65 Eribulin (Liposarkom)

More information

MEDICAL POLICY SUBJECT: TUMOR CHEMORESISTANCE AND CHEMOSENSITIVITY ASSAYS. POLICY NUMBER: CATEGORY: Laboratory Test

MEDICAL POLICY SUBJECT: TUMOR CHEMORESISTANCE AND CHEMOSENSITIVITY ASSAYS. POLICY NUMBER: CATEGORY: Laboratory Test MEDICAL POLICY SUBJECT: TUMOR CHEMORESISTANCE AND PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

What are Clinical Trials

What are Clinical Trials What are Clinical Trials Clinical Trials are systematic studies designed to discover and verify the effects and/or adverse reactions of drugs (pharmacodynamics) and the absorption, distribution, metabolism

More information

Health Technology Assessment & Outcomes Research. AMNOG: 2 years. Friedhelm Leverkus. Director HTA & OR

Health Technology Assessment & Outcomes Research. AMNOG: 2 years. Friedhelm Leverkus. Director HTA & OR AMNOG: 2 years Friedhelm Leverkus Director HTA & OR No additional Benefit FRP Maximum Price is the Price of GBA Comperator (zvt) Additional Benefit Price negotiation with GKV-SV No algorithm is known

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective

More information

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized

More information

National Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007

National Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007 Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature

More information

Interessenskonflikt. 1) Cytosorb Register Planung. 2) Studie Seraph Microbind: ExThera Medical. 3) Fan von Arbeitsgruppe PD Dr.

Interessenskonflikt. 1) Cytosorb Register Planung. 2) Studie Seraph Microbind: ExThera Medical. 3) Fan von Arbeitsgruppe PD Dr. Interessenskonflikt 1) Cytosorb Register Planung 2) Studie Seraph Microbind: ExThera Medical 3) Fan von Arbeitsgruppe PD Dr. David, MHH Cytokinelimination bei Sepsis JanT Kielstein Braunschweig Cytokinelimination

More information

Bevacizumab for the treatment of recurrent advanced ovarian cancer

Bevacizumab for the treatment of recurrent advanced ovarian cancer Bevacizumab for the treatment of recurrent advanced ovarian cancer ERRATUM This report was commissioned by the NIHR HTA Programme as project number 11/40 Page 2 This document contains errata in respect

More information

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT CIOMS FORM SUSPECT ADVERSE REACTION REPORT DE-BFARM-17146522 I. REACTION INFORMATION 1. PATIENT INITIALS 1a. COUNTRY 2. DATE OF BIRTH 2a. AGE 3. SEX 4-6 REACTION ONSET privacy DE DA MO YR [ MedDRA 19.1

More information

OPEN TRIALS Accruals counted until 30-April Current Accrual

OPEN TRIALS Accruals counted until 30-April Current Accrual Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine

More information

Ixekizumab (plaque psoriasis)

Ixekizumab (plaque psoriasis) IQWiG Reports Commission No. A17-30 Ixekizumab (plaque psoriasis) Addendum to Commission A17-07 1 Addendum Commission: A17-30 Version: 1.0 Status: 28 July 2017 1 Translation of addendum A17-30 Ixekizumab

More information

Cellular Biophysics SS Prof. Manfred Radmacher

Cellular Biophysics SS Prof. Manfred Radmacher SS 20007 Manfred Radmacher Immune system has several layers 2 The immune system attacks pathogens macrophage attacking bacteria From: http://pathmicro.med.sc.edu/ghaffar/innate.htm 3 The immune system

More information

LERNCOACHING IN SCHULE. lernen-lernen.eu Jeannine Hohmann

LERNCOACHING IN SCHULE. lernen-lernen.eu Jeannine Hohmann LERNCOACHING IN SCHULE LERNCOACHING IN SCHULE bedeutet eine enge Zusammenarbeit mit den Lehrkräften eine differenzierte Diagnostik zur Förderung die Erstellung eines individuellen Förderkonzeptes eine

More information

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab

More information

Welcome! Here s our agenda for today:

Welcome! Here s our agenda for today: Welcome! Here s our agenda for today: What is ovarian cancer? What causes it? When does genetic testing come in? When are families at risk for ovarian cancer? What are the treatments? 3 things to remember

More information

Hepatozelluläres Karzinom und Cholangiokarzinom was kommt nach Sorafenib? Stefan Kubicka

Hepatozelluläres Karzinom und Cholangiokarzinom was kommt nach Sorafenib? Stefan Kubicka Hepatozelluläres Karzinom und Cholangiokarzinom was kommt nach Sorafenib? Stefan Kubicka SHARP 1 versus Asia-Pacific-Study 2 SHARP S:299/P:303 Asia-Pacific S:150/P:76 End point HR p-value HR p-value OS

More information

Bevacizumab (Avastin)

Bevacizumab (Avastin) Bevacizumab (Avastin) Policy Number: Original Effective Date: MM.04.001 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Prescription Drugs Place(s) of Service:

More information

Performance in Initiating Clinical Research

Performance in Initiating Clinical Research Performance in Initiating Clinical Research January 2016 December 2016 NHS Permissions Site approval Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial

More information

Backgrounder. 1. What are targeted therapies? 2. How do targeted therapies work?

Backgrounder. 1. What are targeted therapies? 2. How do targeted therapies work? Backgrounder TARGETED THERAPIES FOR CANCER 1. What are targeted therapies? 2. How do targeted therapies work? 3. What are some of the different types of targeted therapy? 4. What are the potential benefits

More information

SPEED-02: On the efficiency of a psychological rehabilitation program

SPEED-02: On the efficiency of a psychological rehabilitation program SPEED-02: On the efficiency of a psychological rehabilitation program Don M. DeVol 1, Norbert Hilger 2 und Georg Rudinger 2 1 Institut für Verkehrssicherheit, TÜV Thüringen Fahrzeug GmbH & Co. KG, Erfurt

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 29 th Prioritization 4 th quarter 2016 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Claudia Wild Please note: Within

More information

Neues zur neoadjuvanten Vorbehandlung beim Rektumkarzinom

Neues zur neoadjuvanten Vorbehandlung beim Rektumkarzinom Neues zur neoadjuvanten Vorbehandlung beim Rektumkarzinom Prof. Dr. med. R. Fietkau Strahlenklinik Disclosure I have the following potential confilct(s) of interest to report: Type of affiliation/ financial

More information

Idelalisib Benefit assessment according to 35a Social Code Book V 1

Idelalisib Benefit assessment according to 35a Social Code Book V 1 IQWiG Reports Commission No. A14-35 Idelalisib Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Assessment module I, Sections I 2.1 to I 2.9, and Assessment module II,

More information

MEDICAL PRIOR AUTHORIZATION

MEDICAL PRIOR AUTHORIZATION MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

NCCP Chemotherapy Regimen. Olaparib Monotherapy

NCCP Chemotherapy Regimen. Olaparib Monotherapy Olaparib INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Indicator Maintenance treatment of adult patients with platinum -sensitive relapsed BRCAmutated (germline and/or somatic) - high

More information

Lynparza. Lynparza (olaparib) Description

Lynparza. Lynparza (olaparib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)

More information

Lisdexamfetamine dimesylate Benefit assessment according to 35a Social Code Book V 1

Lisdexamfetamine dimesylate Benefit assessment according to 35a Social Code Book V 1 IQWiG Reports Commission No. A13-24 Lisdexamfetamine dimesylate Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Lisdexamfetamindimesilat

More information

Physical Activity and Cancer

Physical Activity and Cancer Recent Results in Cancer Research 186 Physical Activity and Cancer Bearbeitet von Kerry S. Courneya, Christine M. Friedenreich 1st Edition. 2010. Buch. xiii, 387 S. Hardcover ISBN 978 3 642 04230 0 Format

More information

Horizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma

Horizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology

More information

Vaccine Therapy for Cancer

Vaccine Therapy for Cancer Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President for Medical Affairs Chief, Division of General Oncology Dana-Farber Cancer Institute Disclosures for Lawrence

More information

Radiation Protection Principles for Radioiodine Therapy

Radiation Protection Principles for Radioiodine Therapy Strahlenschutzkommission Geschäftsstelle der Strahlenschutzkommission Postfach 12 06 29 D-53048 Bonn http://www.ssk.de Radiation Protection Principles for Radioiodine Therapy Recommendation by the German

More information

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

Unofficial translation - No legal value. Bundesanzeiger Nr. 229 vom 04. Dezember 1998, S

Unofficial translation - No legal value. Bundesanzeiger Nr. 229 vom 04. Dezember 1998, S Unofficial translation - No legal value Bundesanzeiger Nr. 229 vom 04. Dezember 1998, S. 16 884 Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte - BfArM)

More information

Challenging Genitourinary Tumors: What s New in 2017

Challenging Genitourinary Tumors: What s New in 2017 Challenging Genitourinary Tumors: What s New in 2017 David J. Vaughn, MD Genitourinary Medical Oncology Professor Please note that some of the studies reported in this presentation were presented as an

More information

Sitagliptin/metformin Benefit assessment according to 35a Social Code Book V 1

Sitagliptin/metformin Benefit assessment according to 35a Social Code Book V 1 IQWiG Reports Commission No. A13-03 Sitagliptin/metformin Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sitagliptin/Metformin

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.04 Subject: Avastin Page: 1 of 8 Last Review Date: December 3, 2015 Avastin Description Avastin (bevacizumab)

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 15, 2017 Avastin Description Avastin

More information

Involvement of people affected

Involvement of people affected Involvement of people affected in the dossier assessment 1 1 Translation of the document Beteiligung von Betroffenen bei der Dossierbewertung (Version 1.1; Status: 28 July 2017). Please note: This translation

More information

( Dedrick et al 1978 ) ( Armstrong et al 2006 )

( Dedrick et al 1978 ) ( Armstrong et al 2006 ) ( Dedrick et al 1978 ) ( Armstrong et al 2006 ) ( Dalh O et al 1999 ) ( Hahn GM et al 1983 ) ( G. Multhoff et al 1996 ) ( Helm CW et al 2010 ) ( de Bree E. et al 2015 ) ( Spiliotis J et al. et al

More information

Perampanel Benefit assessment according to 35a Social Code Book V 1

Perampanel Benefit assessment according to 35a Social Code Book V 1 IQWiG Reports Commission No. A14-16 Perampanel Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Perampanel Nutzenbewertung

More information

Checkpointinhibitoren in der Uro-Onkologie. Carsten Grüllich

Checkpointinhibitoren in der Uro-Onkologie. Carsten Grüllich Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: June 22, 2017 Avastin Description Avastin (bevacizumab)

More information

STUDIENLISTE August2018 Studien offen für Accrual DIM Onkologie/Hämatologie und Brustzentrum Kantonsspital St. Gallen

STUDIENLISTE August2018 Studien offen für Accrual DIM Onkologie/Hämatologie und Brustzentrum Kantonsspital St. Gallen 14-007 15/193 2016-00548 L E U K Ä M I E SAKK GRAALL 2014 2016-02559 SAKK 30/10 Hovon 103 Selinexor Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

More information

Vedolizumab Benefit assessment according to 35a Social Code Book V 1

Vedolizumab Benefit assessment according to 35a Social Code Book V 1 IQWiG Reports Commission No. A14-23 Vedolizumab Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Assessment module I, Sections I 2.1 to I 2.6, and Assessment module II,

More information

Tumori eredofamiliari: sorveglianza di donne ad alto rischio

Tumori eredofamiliari: sorveglianza di donne ad alto rischio Tumori eredofamiliari: sorveglianza di donne ad alto rischio 14/01/2018 Dott Matteo Generali AUSL Modena Carpi U.O. Ostetricia e Ginecologia Screening for gynaecologic cancer in genetically predisposed

More information

Eligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment

Eligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment Bevacizumab in combination with Paclitaxel and Carboplatin - Frontline Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (This form must be completed before the first

More information

Studies proceeding under pre HRA-Approval system (NHS Permission)

Studies proceeding under pre HRA-Approval system (NHS Permission) 15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL

More information

Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study

Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study Guo and Peng Journal of Ovarian Research (2017) 10:14 DOI 10.1186/s13048-017-0310-y RESEARCH Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells

More information

Title Cancer Drug Phase Status

Title Cancer Drug Phase Status Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer

More information